Previous 10 | Next 10 |
Search all articles related articles and news articles from the OTCMKTS NASDAQ and NYSE markets.
Bezuclastinib + sunitinib combination therapy reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GI...
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN) today announced that two abstracts, including one for ARV-766 in ...
HOUSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize...
Lifileucel TIL Cell Therapy in Combination with Pembrolizumab DemonstratesDeep, Durable Responses in Frontline Advanced Melanoma Patientsin IOV-CO...
WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the develo...
- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpo...
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB) a clinical-stage biopharmaceutical company developing innovative gamma-del...
Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on ...
SANTA CLARA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- NVIDIA will present at the following event for the financial community: BofA Securities Gl...
Poster highlights durable disease stabilization lasting beyond treatment completion Results suggest a unique, multimodal mechanism of action that...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
26.79%Change Percent:
Standard BioTools Inc. Company Name:
LAB Stock Symbol:
NASDAQ Market:
fluidigm.com Website: